Literature DB >> 12170777

Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.

Liang Qiao1, Adly Yacoub, Robert McKinstry, Jong Sung Park, Ruben Caron, Paul B Fisher, Michael P Hagan, Steven Grant, Paul Dent.   

Abstract

Recent studies have shown that inhibition of stress-induced signaling via the mitogen activated protein kinase (MAPK) pathway can potentiate the toxic effects of chemotherapeutic drugs and ionizing radiation. Because of these observations, we have further investigated the impact upon growth and survival of mammary (MDA-MB-231, MCF7, T47D), prostate (DU145, LNCaP, PC3) and squamous (A431) carcinoma cells following irradiation and combined long-term exposure to MEK1/2 inhibitors. Exposure of carcinoma cells to ionizing radiation resulted in MAPK pathway activation initially (0-4 h) and modestly enhanced MAPK activity at later times (24 h-96 h). Inhibition of radiation-induced MAPK activation using MEK1/2 inhibitors potentiated radiation-induced apoptosis in two waves, at 21-30 h and 96-144 h after exposure. The potentiation of apoptosis was not observed in MCF7, LNCaP, or PC3 cells. At 24 h, the potentiation of apoptosis was independent of radiation dose whereas at 108 h, apoptosis correlated with increasing dose. Removal of the MEK1/2 inhibitor either 6 h or 12 h after exposure abolished the potentiation of apoptosis at 24 h. At this time, the potentiation of apoptosis correlated with cleavage of pro-caspases -8, -9 and -3, and with release of cytochrome c into the cytosol. Inhibition of caspase function using a pan-caspase inhibitor ZVAD blocked the enhanced apoptotic response at 24 h. Selective inhibition of caspase 9 with LEHD or caspase 8 with IETD partially blunted the apoptotic response in MDA-MB-231, DU145 and A431 cells, whereas inhibition of both caspases reduced the response by > 90%. Removal of the MEK1/2 inhibitor either 24 h or 48 h after exposure abolished the potentiation of apoptosis at 108 h. Incubation of cells with ZVAD for 108 h also abolished the potentiation of apoptosis. In general agreement with the finding that prolonged inhibition of MEK1/2 was required to enhance radiation-induced apoptosis at 108 h, omission of MEK1/2 inhibitor from the culture media during assessment of clonogenic survival resulted in either little or no significant alteration in radiosensitivity. Collectively, our data show that combined exposure to radiation and MEK1/2 inhibitors can reduce survival in some, but not all, tumor cell types. Prolonged blunting of MAPK pathway function following radiation exposure is required for MEK1/2 inhibitors to have any effect on carcinoma cell radiosensitivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12170777     DOI: 10.4161/cbt.64

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  9 in total

1.  β-elemene enhances the radiosensitivity of gastric cancer cells by inhibiting Pak1 activation.

Authors:  Jun-Song Liu; Xiang-Ming Che; Shuai Chang; Guang-Lin Qiu; Shi-Cai He; Lin Fan; Wei Zhao; Zheng-Liang Zhang; Shu-Feng Wang
Journal:  World J Gastroenterol       Date:  2015-09-14       Impact factor: 5.742

2.  Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.

Authors:  Christina Wu; Terence M Williams; Evan Wuthrick; Ryan Robb; Amy Webb; Lai Wei; Wei Chen; Sameh Mikhail; Kristen K Ciombor; Dana B Cardin; Cynthia Timmers; Somashekar G Krishna; Mark Arnold; Alan Harzman; Sherif Abdel-Misih; Sameek Roychowdhury; Tanios Bekaii-Saab
Journal:  Clin Cancer Res       Date:  2020-04-06       Impact factor: 12.531

3.  PKA knockdown enhances cell killing in response to radiation and androgen deprivation.

Authors:  Harvey H Hensley; Jean-Michel Hannoun-Levi; Paul Hachem; Zhaomei Mu; Radka Stoyanova; Li-Yan Khor; Sudhir Agrawal; Alan Pollack
Journal:  Int J Cancer       Date:  2010-10-19       Impact factor: 7.396

Review 4.  National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer.

Authors:  Thomas J George; Aaron J Franke; A Bapsi Chakravarthy; Prajnan Das; Arvind Dasari; Bassel F El-Rayes; Theodore S Hong; Timothy J Kinsella; Jerome C Landry; James J Lee; Arta M Monjazeb; Samuel A Jacobs; David Raben; Osama E Rahma; Terence M Williams; Christina Wu; C Norman Coleman; Bhadrasain Vikram; Mansoor M Ahmed
Journal:  Cancer       Date:  2019-04-24       Impact factor: 6.860

Review 5.  Mitogen-activated protein kinases and their role in radiation response.

Authors:  Anupama Munshi; Rajagopal Ramesh
Journal:  Genes Cancer       Date:  2013-09

6.  Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.

Authors:  Rebecca E Schweppe; Anna A Kerege; Vibha Sharma; Joanna M Poczobutt; Arthur Gutierrez-Hartmann; Rachel L Grzywa; Bryan R Haugen
Journal:  Thyroid       Date:  2009-08       Impact factor: 6.568

7.  Arsenic in leukemia: a RSKy business.

Authors:  Paul Dent
Journal:  Cancer Biol Ther       Date:  2013-08-15       Impact factor: 4.742

8.  Mitogen Activated Protein kinase signal transduction pathways in the prostate.

Authors:  Paul D Maroni; Sweaty Koul; Randall B Meacham; Hari K Koul
Journal:  Cell Commun Signal       Date:  2004-06-25       Impact factor: 5.712

9.  Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy.

Authors:  Olga Pernía; Cristobal Belda-Iniesta; Veronica Pulido; María Cortes-Sempere; Carlos Rodriguez; Olga Vera; Javier Soto; Julia Jiménez; Alvaro Taus; Federico Rojo; Edurne Arriola; Ana Rovira; Joan Albanell; M Teresa Macías; Javier de Castro; Rosario Perona; Inmaculada Ibañez de Caceres
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.